Hypothesis Generation and Evaluation in Clinical Trial Design (Abstract/Comunicazione in atti di convegno)

Type

• Abstract/Comunicazione in atti di convegno (Classe)
• Prodotto della ricerca (Classe)

Label

• Hypothesis Generation and Evaluation in Clinical Trial Design (Abstract/Comunicazione in atti di convegno) (literal)

Anno

• 2011-01-01T00:00:00+01:00 (literal)

Alternative label

• Michael Liebman, Sabrina Molinaro (2011)
  Hypothesis Generation and Evaluation in Clinical Trial Design
  in 2011 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2011, Los Angeles, California, 26-28 August 2011
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Michael Liebman, Sabrina Molinaro (literal)

Pagina inizio

• 26 (literal)

Pagina fine

• 26 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

• ID_PUMA: cnr.ifc/2011-A2-009 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#titoloVolume

• Meaningful use of complex medical data : acquiring, analyzing and sharing : August 26 -28, 2011 (literal)

Note

• Abstract (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Strategic Medicine, Inc. ; CNR-IFC, Pisa (literal)

Titolo

• Hypothesis Generation and Evaluation in Clinical Trial Design (literal)

Abstract

• We are developing and implementing novel applications of knowledge representation, ontology development and natural language processing to address issues within the pharmaceutical industry. It is well-documented that the pharmaceutical industry is experiencing significant difficulties in maintaining its historical record of drug approvals and financial achievement because of failures in moving compounds from the discovery pipeline to regulatory approval and commercial success. The critical link in this transition is the clinical trial, heavily regulated and monitored for patient safety and drug efficacy. At present, only about 9% of drugs entering clinical trials succeed in being approved by the regulatory bodies, and unfortunately, that, alone, does not guarantee commercial success as a significant number of approved drugs fail upon introduction into the marketplace. Our approach evaluates and refines the hypothesis upon which these trials are based, establishes a comprehensive approach to an early go/no go decision, identifies risk and improves the probability for success. (literal)

Prodotto di

• Institute of clinical physiology (IFC) (Istituto)
• Epidemiologia sociale (ME.P07.015.003) (Modulo)

Autore CNR

• SABRINA MOLINARO (Unità di personale interno)

Insieme di parole chiave

• Parole chiave di "Hypothesis Generation and Evaluation in Clinical Trial Design" (Insieme di parole chiave)

Incoming links:

Prodotto

• Institute of clinical physiology (IFC) (Istituto)
• Epidemiologia sociale (ME.P07.015.003) (Modulo)

Autore CNR di

• SABRINA MOLINARO (Unità di personale interno)

Insieme di parole chiave di

• Parole chiave di "Hypothesis Generation and Evaluation in Clinical Trial Design" (Insieme di parole chiave)